Central nervous system - Systema nervosum centrale | Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors

excerpt from an edition:

A T L A S - Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors /Second supplemented edition/ - DOI: 10.5281/zenodo.13777292 | ISBN: 978-619-91534-6-8

--------------

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (p.10 form the ATLAS) of transcriptome cell lines inherent in tumors in the Central nervous system(a. & b.), it is concluded that:

- some of the main potential medicines:

(S)-2-(((2S,3R,4S,5S,6R)-3-(((2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-(3-hydroxyphenyl)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (S)-2-hydroxy-2-(3-hydroxyphenyl)acetamide and .../acetic acid ,

(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)but-3-enamide and .../enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-3-methylbut-3-enamide and .../enoic acid ,

(2R,3S)-3-hydroxy-2-(hydroxymethyl)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide and .../butanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (2R,3S)-3,4-dihydroxy-2-(hydroxymethyl)butanamide and .../butanoic acid ,

(1S,4R)-4-carbamoyl-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclopent-2-en-1-yl sulfate and (1S,4R)-4-carboxy-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclopent-2-en-1-yl sulfate in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (1R,4R)-4-carbamoyl-4-hydroxycyclopent-2-en-1-yl sulfate and (1R,4R)-4-carboxy-4-hydroxycyclopent-2-en-1-yl sulfate ,

(R)-2-(4-isopropylphenyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-2-(4-isopropylphenyl)acetamide and .../acetic acid ,

the rest ACCF can be found in the file and the ATLAS ;

- certain medicines for duplication of treatment and/or replacement for medical reasons:

(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide and .../butanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-3-methylbutanamide and .../butanoic acid ,

(E)-2-((2R,4R)-4-hydroxy-2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexylidene)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (E)-2-((2R,4R)-2,4-dihydroxycyclohexylidene)acetamide and .../acetic acid ,

2-((S)-2-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydrobenzofuran-3-yl)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (S)-2-(3-hydroxy-2-oxo-2,3-dihydrobenzofuran-3-yl)acetamide and .../acetic acid ,

the rest ACCF can be found in the file and the ATLAS.

-------

Important! Do not forget to comply with the current clinical control.

The idea timeline: anti-cancer.eu